Figur8, a new sensor platform that captures micrometer precision muscle and joint movement to better diagnose soft tissue injuries, today announced its launch with $7.5 million in seed funding.
The goal of the Boston-based company is to help clinicians make better informed decisions through human movement data.
Clinicians can use the platform, developed by scientists at Massachusetts Institute of Technology and Massachusetts General Hospital, to better assess patients’ movements. The assessments establish a movement health baseline, diagnose movement dysfunction, identify injury risk, enhance exercise routines and monitor progress. Through the assessment, more than one million data points are produced and analyzed by algorithms to generate biomechanical insights.
The sensors quantify precision signals of muscle activity and joint mobility.
“These assessments highlight the weaknesses and anomalies of body segments, which could be a symptom of an injury, disease or simply a target for performance optimization,” said Nan-Wei Gong, Ph.D., CEO of Figur8.
The sensor technology can be placed on multiple parts of the body to collect data and allow the wearers to track movement in their own environment. Sensors gather data including muscle activation timing and intensity with joint angles, acceleration and motion in 3D space. The data gathered are available through the Figur8 web-based platform.
“Measuring musculoskeletal performance and recovery has historically been limited to visual and hands-on assessments, providing little to no quantifiable data,” said Habib Haddad, president and managing director of the E14 Fund. “This makes accurate, large-scale and cost-effective treatment assessments nearly impossible.”
“We believe Figur8 has identified a significant technological breakthrough and look forward to advancing the understanding of human movement through the company’s groundbreaking sensor technologies,” Haddad added.
P5 Health Ventures led the funding, with other investments from E14 Fund and individual investors.
Send this to a friend